Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Colleen Annesley

Showing results (1-10 of 29) with videos related to

Pageof 3
Sort By:
Hematology/Oncology Clinics of North America|July 2, 2022
Chimeric Antigen Receptor T-cell Therapy: Current Status and Clinical Outcomes in Pediatric Hematologic MalignanciesAimee C Talleur, Regina Myers, Colleen Annesley, et al.
Pediatric Blood & Cancer|September 10, 2020
Allopurinol use during pediatric acute lymphoblastic leukemia maintenance therapy safely corrects skewed 6-mercaptopurine metabolism, improving inadequate myelosuppression and reducing gastrointestinal toxicityGordon Cohen, Stacy Cooper, Edward Allan Sison, et al.
Journal for Immunotherapy of Cancer|November 19, 2025
CD28 signaling complexes are correlated with patient outcomes in anti-CD19 41BB-costimulation CAR T cell therapyIsabella H Draper, William Selke, Samuel A Ritmeester-Loy, et al.
Transfusion|March 15, 2018
Lymphocyte apheresis for chimeric antigen receptor T-cell manufacturing in children and young adults with leukemia and neuroblastomaFrancesco Ceppi, Julie Rivers, Colleen Annesley, et al.
Transplantation and Cellular Therapy|September 9, 2023
INSPIRED Symposium Part 2: Prevention and Management of Relapse Following Chimeric Antigen Receptor T Cell Therapy for B Cell Acute Lymphoblastic LeukemiaAdam J Lamble, Amy Moskop, Michael A Pulsipher, et al.
Neuro-Oncology Practice|March 9, 2026
Tumor inflammation-associated neurotoxicity in children with diffuse intrinsic pontine glioma receiving B7-H3-targeting CAR T cells on BrainChild-03Rebecca Ronsley, Michelle Choe, Jason Wright, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 5, 2023
Potential clinical use of azacitidine and MEK inhibitor combination therapy in PTPN11-mutated juvenile myelomonocytic leukemiaSanthosh Kumar Pasupuleti, Karen Chao, Baskar Ramdas, et al.
Experimental Hematology|November 5, 2013
NPMc+ cooperates with Flt3/ITD mutations to cause acute leukemia recapitulating human diseaseRachel Rau, Daniel Magoon, Sarah Greenblatt, et al.
Transplantation and Cellular Therapy|October 13, 2021
Hematopoietic Cell Transplantation after CD19 Chimeric Antigen Receptor T Cell-Induced Acute Lymphoblastic Lymphoma Remission Confers a Leukemia-Free Survival AdvantageCorinne Summers, Qian Vicky Wu, Colleen Annesley, et al.
Transplantation and Cellular Therapy|May 21, 2025
Low Peripheral Blood Counts and Elevated Proinflammatory Cytokines Signal a Poor CD19 Chimeric Antigen Receptor T-cell Response in Acute Lymphoblastic LeukemiaKatelyn Burleigh, Kelly G Stratton, Jenny L Smith, et al.
Pageof 3

Showing results (1-10 of 29) with videos related to

Sort By:
Pageof 3
Hematology/Oncology Clinics of North America|July 2, 2022
Chimeric Antigen Receptor T-cell Therapy: Current Status and Clinical Outcomes in Pediatric Hematologic MalignanciesAimee C Talleur, Regina Myers, Colleen Annesley, et al.
Pediatric Blood & Cancer|September 10, 2020
Allopurinol use during pediatric acute lymphoblastic leukemia maintenance therapy safely corrects skewed 6-mercaptopurine metabolism, improving inadequate myelosuppression and reducing gastrointestinal toxicityGordon Cohen, Stacy Cooper, Edward Allan Sison, et al.
Journal for Immunotherapy of Cancer|November 19, 2025
CD28 signaling complexes are correlated with patient outcomes in anti-CD19 41BB-costimulation CAR T cell therapyIsabella H Draper, William Selke, Samuel A Ritmeester-Loy, et al.
Transfusion|March 15, 2018
Lymphocyte apheresis for chimeric antigen receptor T-cell manufacturing in children and young adults with leukemia and neuroblastomaFrancesco Ceppi, Julie Rivers, Colleen Annesley, et al.
Transplantation and Cellular Therapy|September 9, 2023
INSPIRED Symposium Part 2: Prevention and Management of Relapse Following Chimeric Antigen Receptor T Cell Therapy for B Cell Acute Lymphoblastic LeukemiaAdam J Lamble, Amy Moskop, Michael A Pulsipher, et al.
Neuro-Oncology Practice|March 9, 2026
Tumor inflammation-associated neurotoxicity in children with diffuse intrinsic pontine glioma receiving B7-H3-targeting CAR T cells on BrainChild-03Rebecca Ronsley, Michelle Choe, Jason Wright, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 5, 2023
Potential clinical use of azacitidine and MEK inhibitor combination therapy in PTPN11-mutated juvenile myelomonocytic leukemiaSanthosh Kumar Pasupuleti, Karen Chao, Baskar Ramdas, et al.
Experimental Hematology|November 5, 2013
NPMc+ cooperates with Flt3/ITD mutations to cause acute leukemia recapitulating human diseaseRachel Rau, Daniel Magoon, Sarah Greenblatt, et al.
Transplantation and Cellular Therapy|October 13, 2021
Hematopoietic Cell Transplantation after CD19 Chimeric Antigen Receptor T Cell-Induced Acute Lymphoblastic Lymphoma Remission Confers a Leukemia-Free Survival AdvantageCorinne Summers, Qian Vicky Wu, Colleen Annesley, et al.
Transplantation and Cellular Therapy|May 21, 2025
Low Peripheral Blood Counts and Elevated Proinflammatory Cytokines Signal a Poor CD19 Chimeric Antigen Receptor T-cell Response in Acute Lymphoblastic LeukemiaKatelyn Burleigh, Kelly G Stratton, Jenny L Smith, et al.
Pageof 3